PIK3R1/PIK3R3 Antibody

What are PIK3R1 and PIK3R3 proteins and their significance in cellular signaling?

PIK3R1 and PIK3R3 are regulatory subunits of class IA phosphoinositide 3-kinase (PI3K). PIK3R1 gene products (p85α, p55α, and p50α) are essential for class IA PI3K signaling, binding to catalytic subunits p110α, β, and δ, encoded by PIK3CA, PIK3CB, and PIK3CD respectively. These interactions stabilize and inhibit the catalytic subunits in the basal state and enable responsiveness to upstream stimuli, particularly receptor tyrosine kinase activation. This occurs through two phosphotyrosine-binding SH2 domains shared by all PIK3R1 products, mediating responses to numerous cellular cues . PIK3R3 specifically has been implicated in cancer progression, particularly in liver cancer, where it promotes cell growth by controlling proliferation and cell cycle through the activation of Akt signaling .

How do antibodies against PIK3R1/PIK3R3 differ in their binding epitopes?

PIK3R1/PIK3R3 antibodies are designed to target specific epitopes within these proteins, which affects their utility in various experimental applications. For instance, some antibodies target the C-terminal region (e.g., amino acids 324-353 in PIK3R3) , while others may target other regions such as the regulatory subunit gamma, center domains, or N-terminal regions. The epitope specificity determines the antibody's ability to recognize different isoforms, detect post-translational modifications, or work in various experimental conditions. When selecting an antibody, researchers should consider whether they need to detect specific domains or isoforms of PIK3R1/PIK3R3 based on their experimental questions .

What are the most suitable experimental applications for PIK3R1/PIK3R3 antibodies?

PIK3R1/PIK3R3 antibodies can be utilized across various experimental techniques with differing suitability. They are commonly employed in Western blotting (WB) to detect protein expression levels and molecular weights, immunohistochemistry (IHC) for tissue localization, immunofluorescence (IF) for cellular localization, and enzyme-linked immunosorbent assay (ELISA) for protein quantification. Some antibodies have also been validated for proximity ligation assay (PLA) to detect protein-protein interactions in situ. The selection of the appropriate application depends on the experimental question, with WB being particularly useful for expression analysis, IHC/IF for spatial distribution studies, and ELISA for precise quantification .

How should experimental controls be designed when using PIK3R1/PIK3R3 antibodies?

When designing experiments with PIK3R1/PIK3R3 antibodies, multiple controls are essential for result validation. Positive controls should include samples known to express the target protein (e.g., specific cancer cell lines for PIK3R3 like MHCC97H, HepG2, and Hep3B, which show higher expression compared to normal liver cells) . Negative controls should include samples where the target is absent or knockdown models using siRNA against PIK3R3, as described in liver cancer studies . Loading controls (e.g., housekeeping proteins) are crucial for Western blots to normalize expression levels. Additionally, isotype controls using non-specific antibodies of the same class (e.g., rabbit IgG for a rabbit polyclonal PIK3R3 antibody) should be included to identify non-specific binding .

What are the optimal sample preparation methods for PIK3R1/PIK3R3 detection?

Sample preparation for PIK3R1/PIK3R3 detection varies by experimental technique. For Western blotting, cells or tissues should be lysed in buffers containing protease inhibitors to prevent degradation, with phosphatase inhibitors added when studying phosphorylation states. For immunohistochemistry, fixation with 4% paraformaldehyde is common, while antigen retrieval methods may be necessary to expose epitopes masked during fixation. For immunofluorescence, gentle fixation and permeabilization protocols are recommended to maintain cellular architecture while allowing antibody access. Regardless of technique, samples should be processed promptly after collection and stored appropriately (e.g., at -20°C or -80°C for antibodies) to maintain integrity and prevent repeated freeze-thaw cycles that could degrade the target proteins or antibodies.

What dilution ranges are typically effective for PIK3R1/PIK3R3 antibodies in different applications?

Optimal dilution ranges for PIK3R1/PIK3R3 antibodies vary by application and specific antibody characteristics. For Western blotting, dilutions typically range from 1:500 to 1:2000, while immunohistochemistry often requires more concentrated antibody solutions (1:50 to 1:500). Immunofluorescence applications may use dilutions between 1:100 and 1:1000, and ELISA techniques often employ dilutions from 1:1000 to 1:10000. It is essential to conduct dilution optimization experiments for each new antibody and application combination. Starting with the manufacturer's recommended dilution and testing a range above and below this value allows researchers to identify the optimal concentration that maximizes specific signal while minimizing background noise .

How can PIK3R1/PIK3R3 antibodies be utilized to investigate protein-protein interactions in the PI3K pathway?

PIK3R1/PIK3R3 antibodies are powerful tools for investigating protein-protein interactions within the PI3K pathway through several advanced techniques. Immunoprecipitation (IP) can be used to pull down PIK3R3 and identify binding partners through mass spectrometry or Western blotting of co-precipitated proteins. This approach has revealed interactions between PIK3R3 and downstream molecules like CDKN1C and SMC1A in liver cancer cells . Proximity ligation assay (PLA) using specific antibodies against PIK3R3 and potential binding partners can visualize and quantify interactions in situ with single-molecule resolution. Additionally, chromatin immunoprecipitation (ChIP) can be employed if investigating potential nuclear roles of these proteins. For studying dynamic interactions, researchers can combine these techniques with treatments that activate or inhibit the PI3K pathway, such as growth factors or PI3K inhibitors, to observe how stimulation affects complex formation.

What methodologies can detect post-translational modifications of PIK3R1/PIK3R3 proteins?

Detection of post-translational modifications (PTMs) in PIK3R1/PIK3R3 requires specialized approaches. Phosphorylation, a critical PTM for these proteins, can be detected using phospho-specific antibodies targeting known phosphorylation sites. For novel PTM identification, immunoprecipitation of PIK3R1/PIK3R3 followed by mass spectrometry analysis can reveal phosphorylation, ubiquitination, acetylation, or other modifications. Phos-tag SDS-PAGE, which causes mobility shifts in phosphorylated proteins, can separate different phosphorylated forms before Western blotting. For site-specific studies, researchers can employ site-directed mutagenesis to convert potential modification sites (e.g., changing tyrosine to phenylalanine to prevent phosphorylation at positions like Y458/199) and observe functional effects. Combining these approaches with inhibitors of specific kinases, phosphatases, or other PTM-regulating enzymes can further elucidate the regulation of PIK3R1/PIK3R3 function through post-translational modifications.

How can PIK3R1/PIK3R3 antibodies be applied in cancer research studies?

PIK3R1/PIK3R3 antibodies have become essential tools in cancer research due to the significant role of PI3K signaling in oncogenesis. In tumor tissue microarrays, these antibodies can evaluate expression patterns across large patient cohorts to correlate with clinical outcomes, as demonstrated in studies showing PIK3R3 upregulation in liver cancer correlates with prognosis . For mechanistic investigations, antibodies enable monitoring of PI3K pathway activation through detection of downstream targets like phosphorylated Akt in cell models where PIK3R3 is overexpressed or knocked down. In xenograft models, immunohistochemistry with these antibodies can assess protein expression in tumor sections, correlating with growth rates and treatment responses, as shown in studies where PIK3R3 overexpression significantly increased tumor volume and Ki67 staining in vivo . Additionally, these antibodies facilitate the identification of novel regulatory mechanisms, such as the discovery that PIK3R3 regulates CDKN1C and SMC1A expression through Akt signaling, providing potential therapeutic targets .

What strategies can address non-specific binding when using PIK3R1/PIK3R3 antibodies?

Non-specific binding is a common challenge when working with PIK3R1/PIK3R3 antibodies. To minimize this issue, researchers should implement several strategies: (1) Optimize blocking conditions using 3-5% BSA or milk in TBS-T, potentially testing different blocking agents to identify the most effective option; (2) Increase washing duration and frequency between antibody incubations, using TBS-T with 0.1-0.3% Tween-20; (3) Titrate antibody concentrations to find the minimum concentration giving detectable specific signal; (4) Pre-adsorb the antibody with non-specific proteins or use commercially available blocking peptides; (5) For tissue IHC, incorporate endogenous peroxidase blocking steps and consider biotin/avidin blocking if using biotinylated secondary antibodies; (6) Verify antibody specificity using positive and negative controls, including knockdown samples where PIK3R3 is silenced by siRNA . These approaches should be systematically tested to determine the optimal conditions for each specific experimental system and antibody.

How can researchers validate PIK3R1/PIK3R3 antibody specificity for their experimental system?

Rigorous validation of PIK3R1/PIK3R3 antibody specificity is crucial for experimental reliability. A comprehensive validation approach includes: (1) Genetic knockdown/knockout verification - use siRNA, shRNA, or CRISPR-Cas9 to reduce or eliminate target expression, then confirm signal reduction with the antibody, as demonstrated in PIK3R3 knockdown experiments in liver cancer cell lines ; (2) Overexpression systems - transfect cells with PIK3R1/PIK3R3 expression constructs and verify increased antibody signal; (3) Peptide competition assays - pre-incubate the antibody with the immunizing peptide before application to samples, which should eliminate specific binding; (4) Cross-reactivity testing - evaluate antibody performance in samples from multiple species relevant to the research; (5) Multiple antibody comparison - use different antibodies targeting distinct epitopes of the same protein to confirm consistent detection patterns; (6) Western blotting - verify single bands at the expected molecular weight (approximately 55-85 kDa depending on the specific isoform). Implementation of these validation steps ensures confidence in antibody-derived data and facilitates accurate interpretation of experimental results.

What factors might cause variability in PIK3R1/PIK3R3 antibody performance across different experiments?

Several factors can contribute to variability in PIK3R1/PIK3R3 antibody performance across experiments. Antibody storage conditions significantly impact stability - improper storage or repeated freeze-thaw cycles can degrade antibody quality, necessitating storage at -20°C or -80°C with minimal freeze-thaw cycles . Sample preparation variations, including differences in fixation duration, lysis buffer composition, or protein extraction efficiency, can affect epitope availability and detection sensitivity. Lot-to-lot variations in commercially produced antibodies may occur due to differences in immunization responses or purification processes, making it advisable to record lot numbers and purchase larger quantities of a single lot for extended studies. Environmental factors such as incubation temperature, time, and buffer pH can influence antibody-epitope binding kinetics. Additionally, variations in detection systems (chromogenic vs. fluorescent) or imaging equipment settings may affect signal intensity and background levels. To minimize variability, researchers should standardize protocols, include internal controls in each experiment, and maintain detailed records of all experimental conditions and reagent sources.

How should researchers interpret quantitative differences in PIK3R1 versus PIK3R3 expression patterns?

Interpreting quantitative differences between PIK3R1 and PIK3R3 expression requires careful consideration of several factors. When analyzing expression data, researchers should note that PIK3R3 shows more pronounced variation in liver cancer compared to normal tissues, contrasting with PIK3R1 and PIK3R2 patterns . This differential expression may indicate distinct regulatory mechanisms and functional roles in pathological conditions. Quantification should employ appropriate normalization methods using housekeeping genes or proteins whose expression remains stable across experimental conditions. When comparing across different tissue or cell types, consider tissue-specific baseline expression levels and evaluate fold changes rather than absolute values. Additionally, expression data should be correlated with functional outcomes, as demonstrated in studies where PIK3R3 upregulation in HCC correlated with specific clinical parameters and promoted increased cell proliferation . Finally, it's essential to integrate expression data with pathway activity measurements (e.g., phosphorylated Akt levels) to understand the functional consequences of expression differences between these related but distinct regulatory subunits.

What analytical approaches help distinguish true signal from background in complex tissue samples?

Distinguishing true PIK3R1/PIK3R3 signal from background in complex tissue samples requires sophisticated analytical approaches. Digital image analysis software can quantify staining intensity objectively, eliminating observer bias and enabling threshold-based signal discrimination. Dual staining approaches combining PIK3R1/PIK3R3 antibodies with cell-type-specific markers help identify which cell populations express the target protein within heterogeneous tissues. Spectral unmixing techniques can separate overlapping fluorophore signals in multiplexed immunofluorescence experiments, allowing simultaneous detection of multiple targets. Comparison with negative controls (isotype-matched non-specific antibodies) and positive controls (tissues known to express the target) provides reference points for signal authenticity. When analyzing immunohistochemistry data, consider using the H-score method, which accounts for both staining intensity and percentage of positive cells, providing a more comprehensive evaluation than simple positive/negative classifications. For immunofluorescence, z-stack imaging and deconvolution can improve signal-to-noise ratios by eliminating out-of-focus light, particularly valuable when examining subcellular localization of PIK3R1/PIK3R3 proteins.

How can PIK3R1/PIK3R3 antibody data be integrated with other experimental approaches to validate research findings?